ClinicalTrials.gg
RecruitingNCT07401225Updated Jul 13, 2026

TMS for PTSD in Youth

An interventional study of MagPro R30 with robotic arm in Post Traumatic Stress Disorder (PTSD), sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio — 8 open to participants now, 8 under way, none of them phase 3. Stress Disorders, Post-Traumatic · The University of Texas Health Science Center at San Antonio.

Planned enrollment
20th of 25
20 · median 49
Started
2026
with 3 others
No phase
20 of 27
6 open now
Registered
25th of 27
by date

Among the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, this one is the 20th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, and was the 25th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

8 of the 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 12 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Stress Disorders, Post-Traumatic by The University of Texas Health Science Center at San Antonio, or all of them as a file.
02

Study summary

The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.

Read the detailed description

Trauma is a common occurrence among youth. Almost 60% of American youths experience a traumatic event before age 18, such as physical or sexual abuse, sudden loss of caregivers, or witnessing violence in the community or the home. Distress after a significantly traumatic event is to be expected, but for some youths, symptoms of posttraumatic stress disorder (PTSD) linger for months or years, and can become chronic if left untreated. Symptoms of PTSD can include upsetting memories, avoidance of reminders, and emotional numbing, and other symptoms. These symptoms can create difficulties for family relationships, friendships, and schoolwork. Currently, the most effective treatment for PTSD is talk therapy (trauma-focused psychotherapy). However, sometimes young people continue to have symptoms of PTSD after completing talk therapy, and it is currently not known the best way to help with these persistent symptoms.

In this study, the total length of time participants will be involved in the study is about 16-weeks. During that time, participants will be asked to attend approximately 6 research visits and 10 treatment visits, for a total of 16 visits. The 6 research visits include a screening visit, an interview visit, 2 MRI visits, and 2 follow-up visits. The screening, interview, and follow-up visits can be completed virtually, over zoom. The study will include 2 MRI visits and 10 treatment visits. Virtual follow-up visits will be conducted 1 and 3 months after completion of treatment and will include interviews and questionnaires about participants symptoms.

03

Conditions studied

  • Post Traumatic Stress Disorder (PTSD)

Keywords

  • Transcranial Magnetic Stimulation
  • Transcranial Magnetic Stimulation (TMS)
04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females; Age 12-20
  2. Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community
  3. Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index
  4. Willing to attend 10 TMS treatment sessions within a 30-day period
  5. Fluent in English

Exclusion criteria

Exclusion Criteria:

  1. History of seizures
  2. History of head injury with loss of consciousness and concussive sequelae
  3. Brain abnormality such as tumor or other observable abnormality
  4. Currently receiving psychotherapy or TMS treatment
  5. Currently pregnant
  6. MRI (metal in body, orthodontic braces)
  7. Diagnosis of bipolar 1 or a psychotic disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TMS treatment group

    Each treatment visit will take about 1.5 hours. Participants will receive up to 4 TMS treatment sessions during the visit, with each session lasting about 10-minutes. After the TMS sessions, there will be a brief visit with a psychotherapist.

    Device: MagPro R30 with robotic arm

Interventions

  • DeviceMagPro R30 with robotic arm

    TMS will be delivered to the right anterior dorsolateral frontal cortex. The accelerated protocol consists of 1,800 TMS pulses per session, delivered at intensity ranges designed to deliver depth-corrected E-fields of 80-95 volts/meter. The exact intensity will be determined when the participant's treatment plan is developed. Once a patient's TMS treatment plan has been created, it will be used for every treatment session for that participant.

06

What researchers measure

Primary outcomes

  1. Side Effects of TMS treatment

    number of side effects reported per participant

    Time frame: Day 1 of treatment through Day 30

  2. Number of Adverse Events

    Number of adverse events experienced by study participants through the treatment phase of the study

    Time frame: Day 1 of treatment through Day 30

  3. Completion rate of Treatment

    Number of participants that completed the TMS treatment

    Time frame: Day 1 of treatment through Day 30

Secondary outcomes

  1. Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)(CAPS-5)

    The CAPS-5 score range for total symptom severity is 0 to 80, calculated by summing the severity ratings (0-4) for 20 PTSD symptoms, with higher scores indicating greater severity; scores below 31-33 often suggest subclinical or non-diagnostic levels, while scores above this range can indicate probable PTSD.

    Time frame: Baseline to 90 days

  2. Assessment of Depression using Patient Health Questionnaire-9 (PHQ-9)

    Patients rate 9 common depressive symptoms (e.g., feeling down, trouble sleeping, low energy, poor appetite, concentration issues, feeling bad about self, restlessness/slowed down, thoughts of being better off dead/hurting self). Scoring: Each symptom gets 0-3 points, totaling 0-27. A lower score indicates less depression.

    Time frame: Baseline to Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — requests for data will be considered on a case-by-case basis

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
May 9, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07401225
Collaborators
Texas Child Mental Health Care Consortium: TCMHCC
Responsible party
Amy Garrett, PhD (Associate Professor, The University of Texas Health Science Center at San Antonio) — Principal investigator
First posted
Feb 10, 2026
Start date
May 9, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Amy S Garrett, PhD
Contact
GarrettAS@uthscsa.edu
210-567-8189
Amy S Garrett, PhD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion